Prognostic value of circulating tumor DNA for minimal residual disease detection in ovarian cancer: A systematic review and meta-analysis

Our findings suggest that ctDNA is a novel instrument for MRD detection, and its presence serves as a potent prognostic indicator for recurrence and mortality in ovarian cancer. These results support integrating ctDNA into clinical trial designs and highlight its potential for risk-adapted surveillance and treatment strategies.